Stand und Perspektiven der Chemotherapie beim anthrazyklinvorbehandelten Mammakarzinom – Ergebnisse randomisierter Studien

Randomized trials performed in anthracycline-pretreated breast
cancer patients have demonstrated good activity of taxane-based
regimens. In a face to face comparison, single-agent docetaxel
proved to be significantly more effective than paclitaxel.
Treatment with docetaxel was also associated with an increased
incidence of grade grade-3/4 toxicities in this trial. Antitumor
activity of taxane-based combination regimens was clearly superior
to single-agent therapy in two trials. As anticipated,
treatment-associated toxicity was greater with combination
regimens, but this did not affect quality of life.